• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-term daily drinking linked to stiffening of the arteries in men
Conclusion This prospective cohort study aimed to look at the relationship between long-term alcohol patterns and stiffness of the arteries as a potential indicator of cardiovascular health. The researchers found men who were stable heavy drinkers had stiffer arteries compared with stable moderate drinkers. Male former drinkers also had increasingly stiffer arteries over the following four to five years compared with consistent moderate drinkers. There were no significant findings seen for women at all. But this study does have limitations: This type of study is not able to prove drinking causes stiffness of the arter...
Source: NHS News Feed - February 21, 2017 Category: Consumer Health News Tags: Heart/lungs Food/diet Source Type: news

Sauna use linked to longer life, fewer fatal heart problems
After shoveling for days, breaking up ice dams, and now shivering in this week’s frigid temperatures, I wouldn’t mind sitting in a sauna for a bit. A new report in JAMA Internal Medicine makes this pastime even more appealing: regularly spending time in a sauna may help keep the heart healthy and extend life. Researchers from the University of Eastern Finland tracked 2,300 middle-aged men for an average of 20 years. They categorized the men into three groups according to how often they used a sauna each week. The men spent an average of 14 minutes per visit baking in 175° F heat. Over the course of the study, ...
Source: New Harvard Health Information - February 25, 2015 Category: Consumer Health News Authors: Beverly Merz Tags: Complementary and alternative medicine Heart Health sauna Source Type: news